Share on StockTwits

Pacific Biosciences of California (NASDAQ:PACB) Director William W. Ericson bought 135,155 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 18th. The shares were purchased at an average cost of $5.09 per share, for a total transaction of $687,938.95. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Pacific Biosciences of California (NASDAQ:PACB) traded down 3.91% during mid-day trading on Wednesday, hitting $4.91. 220,976 shares of the company’s stock traded hands. Pacific Biosciences of California has a one year low of $3.32 and a one year high of $8.20. The stock’s 50-day moving average is $5.20 and its 200-day moving average is $5.46. The company’s market cap is $346.8 million.

Pacific Biosciences of California (NASDAQ:PACB) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.12. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the previous year, the company posted ($0.33) earnings per share. The company’s revenue for the quarter was up 90.0% on a year-over-year basis. Analysts expect that Pacific Biosciences of California will post $-1.07 EPS for the current fiscal year.

Pacific Biosciences, Inc develops Deoxyribonucleic Acid (NASDAQ:PACB) sequencing platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.